CN117025607A - 一种用于抑制病毒的miRNA及其应用 - Google Patents
一种用于抑制病毒的miRNA及其应用 Download PDFInfo
- Publication number
- CN117025607A CN117025607A CN202311009629.8A CN202311009629A CN117025607A CN 117025607 A CN117025607 A CN 117025607A CN 202311009629 A CN202311009629 A CN 202311009629A CN 117025607 A CN117025607 A CN 117025607A
- Authority
- CN
- China
- Prior art keywords
- mirna
- virus
- cov
- sars
- coronavirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091070501 miRNA Proteins 0.000 title claims abstract description 75
- 239000002679 microRNA Substances 0.000 title claims abstract description 64
- 241000700605 Viruses Species 0.000 title claims abstract description 53
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 16
- 241000711573 Coronaviridae Species 0.000 claims abstract description 19
- 239000003814 drug Substances 0.000 claims abstract description 10
- 239000003112 inhibitor Substances 0.000 claims abstract description 8
- 210000001808 exosome Anatomy 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 14
- 230000029812 viral genome replication Effects 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 208000024891 symptom Diseases 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 239000003443 antiviral agent Substances 0.000 claims 2
- 230000010076 replication Effects 0.000 abstract description 11
- 230000000840 anti-viral effect Effects 0.000 abstract description 9
- 102100031673 Corneodesmosin Human genes 0.000 abstract description 5
- 101710139375 Corneodesmosin Proteins 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 2
- 239000000284 extract Substances 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 24
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 15
- 239000006228 supernatant Substances 0.000 description 10
- 238000012163 sequencing technique Methods 0.000 description 9
- 241000132011 Atractylodes lancea Species 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 108091031173 miR7782 stem-loop Proteins 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241000315672 SARS coronavirus Species 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 108091036095 Asparagus officinalis miR159 stem-loop Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108091082857 Brachypodium distachyon miR7782 stem-loop Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 108020004417 Untranslated RNA Proteins 0.000 description 2
- 102000039634 Untranslated RNA Human genes 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000035992 intercellular communication Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 108091027963 non-coding RNA Proteins 0.000 description 2
- 102000042567 non-coding RNA Human genes 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 238000004627 transmission electron microscopy Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 208000025721 COVID-19 Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000001528 Coronaviridae Infections Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108091030146 MiRBase Proteins 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 108091005774 SARS-CoV-2 proteins Proteins 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000007622 bioinformatic analysis Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000003229 cytophilic effect Effects 0.000 description 1
- 238000012350 deep sequencing Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 208000026425 severe pneumonia Diseases 0.000 description 1
- 108091069025 single-strand RNA Proteins 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000007444 viral RNA synthesis Effects 0.000 description 1
- 230000006648 viral gene expression Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Botany (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明提供了一种用于抑制病毒的miRNA及其应用,属于生物医药技术领域;本发明从茅苍术中提取出序列如SEQ.ID.NO.1或SEQ.ID.NO.2所示的miRNA;所述miRNA与冠状病毒S蛋白的部分区域完全匹配且具有一定的细胞亲和力,能够抑制冠状病毒的复制,具有抗病毒的能力;所述miRNA在制成病毒抑制剂中具有很好的应用。
Description
技术领域
本发明属于生物医药技术领域,具体涉及一种用于抑制病毒的miRNA及其应用。
背景技术
冠状病毒(coronavirus,CoV)为正链单股RNA病毒,亚科分为α、β、γ、δ四个属,可以感染人类的有7种,其中SARS冠状病毒(SARS-CoV)、中东呼吸综合症冠状病毒(MERS-CoV or HCoV-EMC)、新型冠状病毒(SARS-CoV-2)致病性较强,均可引起重症肺炎。新型冠状病毒感染(coronavirus disease2019,SARS-COV-2)是由严重急性呼吸系统综合征冠状病毒2型(severe acute respiratory syndrome coronavirus 2,SARS-CoV-2)感染导致的急性呼吸道传染病,病毒感染人体以后,通过与肺泡上皮的血管紧张素转化酶受体Ⅱ结合进入人体,可以使肺泡上皮细胞脱落,细胞被病毒感染以后,病毒在细胞内进行核酸的转录、复制,细胞会出现坏死,坏死的肺泡上皮细胞被淋巴细胞所清除,从而引起肺部炎症。
miRNA与机体代谢、免疫、肿瘤等生理病理过程有密切联系,已经成为人们在生命科学研究中的热点之一。作为治疗剂,miRNAs在治疗各种类型的癌症、心脏病、哮喘、肺炎等方面得到了广泛的分析和记录。miRNAs具有抗病毒的潜力,其可以通过影响病毒RNA的合成、阻止病毒复制、抑制亲病毒蛋白或将病毒推入潜伏期来实现抗病毒的目的,其还可以通过抑制蛋白质翻译和诱导病毒mRNA降解来抑制病毒基因的表达。
外泌体(exosomes)是活细胞分泌的来源于晚期核内体(也称为多囊泡体)的膜性小囊泡,其天然存在于真核生物的体液中,包括血液、尿液、唾液、母乳、脑脊液以及细胞培养液。多数报道中的外泌体是直径在40~100nm,密度在1.13~1.21g/ml的小囊泡。近几年,研究发现外泌体中含有细胞特异的蛋白质、脂质。外泌体功能取决于其所来源的细胞类型,其可参与细胞间通讯、参与到机体免疫应答、抗原提呈、细胞迁移、细胞分化、肿瘤侵袭等方方面面。
化湿败毒方由14味中药组成,其中茅苍术是化湿败毒方的主要成分之一,现代医学研究表明茅苍术的干燥块茎具有调节免疫、抗肿瘤等作用。因此,可以从茅苍术中寻找能够一种用于抑制冠状病毒的RNA。
发明内容
针对现有技术中存在不足,本发明提供了一种用于抑制病毒的miRNA及其应用;本发明从茅苍术中提取出核苷酸序列如SEQ.ID.NO.1或SEQ.ID.NO.2所示的miRNA;所述miRNA与冠状病毒S蛋白的部分区域完全匹配且具有一定的细胞亲和力,能够抑制冠状病毒的复制,具有抗病毒的能力;所述miRNA在制成病毒抑制剂中具有很好的应用。
为了达到上述目的,本发明采用以下技术方案:
本发明首先提供了一种用于抑制病毒的miRNA,所述miRNA的核苷酸序列如SEQ.ID.NO.1或SEQ.ID.NO.2所示;
SEQ.ID.NO.1:ACCUGCUCUGAUACCAUGUUGUGA;
SEQ.ID.NO.2:UUUGGAUUGAAGGGAGCUCUA。
本发明还提供了一种生物安全的载体,所述载体中包含上述miRNA。
优选地,所述载体包括外泌体。
本发明还提供上述miRNA或载体的应用,所述应用包括:
(A)抑制病毒的复制;和/或
(B)制备病毒抑制剂;和/或
(C)制备预防和/或治疗病毒引起的病症及其症状的药物。
优选地,所述病毒包括冠状病毒,更优选为SARS-COV-2病毒。
本发明还提供了一种非治疗目的的抑制病毒复制的方法,所述方法为采用上述miRNA和/或载体抑制病毒复制。
优选地,所述病毒包括冠状病毒,更优选为SARS-COV-2病毒。
本发明还提供了一种病毒抑制剂,所述病毒抑制剂以上述miRNA和/或载体为活性成分。
优选地,所述病毒包括冠状病毒,更优选为SARS-COV-2病毒。
本发明还提供了一种预防和/或治疗病毒引起的病症及其症状的药物,所述药物以上述miRNA和/或载体为活性成分。
优选地,所述病毒包括冠状病毒,更优选为SARS-COV-2病毒。
与现有技术相比,本发明的有益效果在于:
本发明从茅苍术中筛选获得miRNA,所述miRNA与SARS-COV-2病毒S蛋白的部分区域完全匹配,并且具有一定的亲细胞和力,因此能够一定程度上抑制SARS-COV-2病毒的复制;所述miRNA具有抗病毒能力的效果,能够用于制备病毒抑制剂。
本发明将miRNA导入到生物安全的载体中,例如可以将miRNA转染至HEK293T细胞中,从HEK293T细胞中分离外泌体,借助生物安全的载体,阻断SARS-COV-2病毒S蛋白的合成,抑制SARS-COV-2病毒侵袭能力,快速高效地降低病人体内的病毒拷贝数,从而达到抑制新冠病毒的目的。
本发明中以外泌体为载体,所述外泌体被视为特异性分泌的膜泡,参与细胞间通讯。外泌体里含有蛋白质、miRNA等多种生物活性物质,通过膜融合作为细胞间的桥梁,将miRNA和蛋白质等内容物传递给其他细胞。本发明中所述miRNA可以人工合成,所述外泌体可以在低温下储存。并且,所述miRNA和外泌体成本低,可以实现大规模的生产,能够用于抑制病毒的复制、制备病毒抑制剂或制备预防和/或治疗病毒引起的病症及其症状的药物。所述miRNA和外泌体对充分发挥中医药救治新冠病毒感染中具有重要意义。
附图说明
图1为茅苍术测序后miRNA富集程度的结果图(A)和病毒基因组上miRNA潜在的靶向结合位点数量图(B),其中A1~A5为158个miRNA的富集程度。
图2为细胞培养基收集外泌体的示意图(A)、miRNA转染后透射电镜观察HEK293T细胞外泌体的形态图(B)以及Western Blot实验验证外泌体标志蛋白的结果图(C);其中B1为空白对照,B2和B3是分别含两种miRNA转染的外泌体。
图3为HEK293T细胞外泌体miRNA抗病毒活性的鉴定流程图(A)和qPCR(n=3)定量检测感染细胞培养上清液中的病毒产量(B),B1~B2是由两种miRNA转染HEK293T细胞后分泌的外泌体抑制SARS-CoV-2复制的实验研究。
具体实施方式
下面结合附图以及具体实施例对本发明作进一步的说明,但本发明的保护范围并不限于此。特别需要指出的是,所有类似的替换和改动对本领域技术人员来说是显而易见的,它们都被视为包括在本发明。本发明的方法及应用已经通过较佳实施例进行了描述,相关人员明显能在不脱离本发明内容、精神和范围内对本文所述的方法和应用进行改动或适当变更与组合,来实现和应用本发明技术。以下实施案例中的方法、设备、材料,如果未进行特别说明,均为本领域常规方法、设备和材料,均可由市场购得。
实施例1:miRNA的获取及测序分析
(1)miRNA的提取:
取适量的茅苍术样品,倒入液氮进行研磨,此过程要迅速,保持研钵中有液氮,采用通用植物microRNA提取试剂盒(无锡百泰克生物技术有限公司)从茅苍术中提取miRNA,整个实验过程中要使用无酶无菌的枪头、EP管,从而降低miRNA的降解。通过增大植物提取样品量,在提取过程中增加裂解液剂量,增加氯仿的使用次数,尽可能使核蛋白体分解,以减少植物体蛋白污染。
(2)miRNA测序分析:
委托百迈克生物科技有限公司对步骤(1)中提取到的miRNA进行测序分析,分析步骤如下:
(A)使用Illumina深度测序技术对miRNA片段进行测序,发现富集度高的miRNA;
(B)采用novaseq6000 PE150平台对茅苍术中miRNA进行测序,平均每个样品产生10M clean reads(单个样品数据量往下浮动小于5%)将比对到参考基因组的reads与miRbase数据库中已知的miRNA的成熟序列及其上游2nt与下游5nt的范围进行比对,比对最多允许一个错配,测序结果如图1所示。
图1为茅苍术测序后miRNA富集程度的结果图(A)和病毒基因组上miRNA潜在的靶向结合位点数量图(B),从图1A中可以看出,茅苍术中存在许多miRNA的表达,通过测序中发现了158个miRNA,其中有5个富集程度高的miRNA。
将上述5个富集程度高的miRNA分别输入RNAhybrid软件与冠状病毒SARS-COV-2全基因组序列(NC_045512.2)进行比对分析,获得了针对SARS-COV-2病毒基因组具有靶向能力和结合位点较强的miRNA。通过比对发现,2个miRNA对SARS-COV-2病毒的基因组具有靶向能力,所述miRNA分别为bdi-miR7782-3p和aof-miR159,其核苷酸序列如下所示:
bdi-miR7782-3p:ACCUGCUCUGAUACCAUGUUGUGA(SEQ.ID.NO.1);
aof-miR159:UUUGGAUUGAAGGGAGCUCUA(SEQ.ID.NO.2)。
为了验证上述两个miRNA抗SARS-COV-2的效果,本实施例中通过生物信息学分析预测了2个miRNA在SARS-CoV-2基因组中的结合位点,预测结果如图1B所示。从图中可以看出,miRNA7782-3p与SARS-CoV-2基因组有129个结合位点,miRNA159与SARS-CoV-2基因组有47个结合位点。因此,我们推测上述2个miRNA可能能够抑制SARS-CoV-2蛋白的翻译。
实施例2:miRNA的转染及外泌体的制备
(1)将HEK293T细胞(普诺赛生命科技有限公司)在37℃、5%CO2、10%胎牛血清(南京森贝伽生物科技有限公司)和1%青霉素-链霉素(南京森贝伽生物科技有限公司)的高糖DMEM(Gibco)中培养。待HEK293T细胞复苏、传代后,根据EL转染试剂盒(北京全式金生物技术有限公司)说明,对HEK293T细胞进行转染。将合成2个miRNA或对照非编码RNA(ncRNA)转染至HEK293T细胞中,转染4-6后小时更换培养基,继续培养48后收集上清。
(2)采用如图2A所示的方法从细胞上清液中制备外泌体,具体步骤为:
根据上述(1)的步骤,分别取ncRNA、miR7782-3p、miR159转染后的细胞上清液,先以4℃、500×g的条件离心10min,去沉淀取上清后,再以4℃、2000×g的条件离心10min,去沉淀取上清后,最后以4℃、10000×g的条件离心20min后取上清液,将得到的上清液使用0.22μm孔径过滤器过滤,然后从收获的上清液在4℃、110000×g的条件离心75min(离心2次)后分离外泌体,弃去沉淀,用PBS洗涤两次,将外泌体重悬浮于PBS中,使用0.22μm孔径过滤器过滤,得到外泌体,-80℃保存,备用。
在透射电镜下观察HEK293T细胞外泌体的形态,观测结果如图2B所示。从图2B中可以看出,转染之后miR7782-3p、miR159这2个miRNA的细胞外泌体个体完整,观察到小囊泡,可见明显完整膜结构,呈茶托样。Western Blot实验验证外泌体标志蛋白的结果如2C所示。
实施例3:miRNA抗病毒成分的验证
将非洲绿猴肾VeroE6细胞系(普诺赛生命科技有限公司)在37℃、5%CO2条件下,在生长培养基(MEM培养基中加入10%胎牛血清和1% P/S)中培养。SARS-CoV-2毒株(NC_045512.2)在Vero E6细胞中繁殖,有关于SARS-CoV-2活病毒的实验都是在P3实验室进行。
为了评价上述miRNA对SARS-CoV-2复制的直接影响,采用如图3A所示的鉴定流程来评价HEK293T细胞外泌体miRNA的抗病毒活性,具体方法如下所示:
分别将分离的含miR7782-3p、miR159和ncRNA的外泌体与5×104VeroE6细胞在生长培养基中孵育8h,孵育结束后更换新的生长培养基并感染SARS-CoV-2。在感染后24h,通过实时定量RT-PCR(qRT-PCR)定量检测细胞上清液中病毒的拷贝数来评价疗效,检测结果如图3B所示。
从图3B中可以看出,细胞外泌体miR7782-3p对SARS-CoV-2病毒复制的抑制率为68%(从4.32×109到1.28×109拷贝/mL);细胞外泌体miR159对SARS-CoV-2病毒复制的抑制率为26%(从4.12×109到3.05×109拷贝/mL)。可见,细胞外泌体miR7782-3p和miR159能够不同程度的抑制SARS-CoV-2病毒的复制。
综上所述,本发明提供的2个miRNA与SARS-COV-2病毒S蛋白的部分区域完全匹配,并且具有一定的亲细胞和力,因此能够一定程度上抑制SARS-COV-2病毒的复制;所述miRNA具有抗病毒能力的效果,能够用于制备病毒抑制剂。
所述实施例为本发明的优选的实施方式,但本发明并不限于上述实施方式,在不背离本发明的实质内容的情况下,本领域技术人员能够做出的任何显而易见的改进、替换或变型均属于本发明的保护范围。
Claims (10)
1.一种用于抑制病毒的miRNA,其特征在于,所述miRNA的核苷酸序列如SEQ.ID.NO.1或SEQ.ID.NO.2所示;
SEQ.ID.NO.1:ACCUGCUCUGAUACCAUGUUGUGA;
SEQ.ID.NO.2:UUUGGAUUGAAGGGAGCUCUA。
2.一种载体,其特征在于,所述载体中包括权利要求1所述的miRNA。
3.根据权利要求2所述的载体,其特征在于,所述载体包含外泌体。
4.权利要求1所述的miRNA或权利要求2~3任一项所述的载体的应用,其特征在于,所述应用包括:
(A)抑制病毒的复制;和/或
(B)制备病毒抑制剂;和/或
(C)制备预防和/或治疗病毒引起的病症及其症状的药物。
5.根据权利要求4所述的应用,其特征在于,所述病毒包括冠状病毒,更优选为SARS-COV-2病毒。
6.一种非治疗目的的抑制病毒复制的方法,其特征在于,所述方法为采用权利要求1所述的miRNA和/或权利要求2~3任一项所述的载体抑制病毒复制。
7.根据权利要求6所述的方法,其特征在于,所述病毒包括冠状病毒,更优选为SARS-COV-2病毒。
8.一种病毒抑制剂,其特征在于,所述病毒抑制剂以权利要求1所述的miRNA和/或权利要求2~3任一项所述的载体为活性成分。
9.根据权利要求8所述的病毒抑制剂,其特征在于,所述病毒包括冠状病毒,更优选为SARS-COV-2病毒。
10.一种预防和/或治疗病毒引起的病症及其症状的药物,所述药物以权利要求1所述的miRNA和/或权利要求2~3任一项所述的载体为活性成分。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311009629.8A CN117025607A (zh) | 2023-08-11 | 2023-08-11 | 一种用于抑制病毒的miRNA及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311009629.8A CN117025607A (zh) | 2023-08-11 | 2023-08-11 | 一种用于抑制病毒的miRNA及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117025607A true CN117025607A (zh) | 2023-11-10 |
Family
ID=88644293
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311009629.8A Pending CN117025607A (zh) | 2023-08-11 | 2023-08-11 | 一种用于抑制病毒的miRNA及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117025607A (zh) |
-
2023
- 2023-08-11 CN CN202311009629.8A patent/CN117025607A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR970005273B1 (ko) | 거대세포 바이러스 감염의 효과를 완화시키기 위한 올리고뉴클레오티드 | |
JP2015526080A (ja) | 植物のマイクロリボ核酸の抽出、製造およびその応用 | |
LU101943B1 (en) | Method for preparing novel coronavirus pneumonia bivalent vaccine | |
KR20170103697A (ko) | 엑소좀 또는 엑소좀 유래 리보핵산을 포함하는 간섬유증 예방 또는 치료용 조성물 | |
Yuan et al. | Effect of exosomes derived from mir-126-modified mesenchymal stem cells on the repair process of spinal cord injury in rats. | |
CN101928782B (zh) | 同时检测猪繁殖与呼吸综合征病毒经典株和变异株的引物和试剂盒 | |
CN112920989A (zh) | 一种肝脏类器官模型及其建立方法、用途以及治疗肝细胞铁死亡的药物组合物 | |
CN110075124A (zh) | AMSC-MALAT1-Exo用于制备治疗肝脏疾病的药物中的应用及其制备方法 | |
CN107586780B (zh) | 一种抑制猪繁殖与呼吸综合征病毒的长链非编码rna | |
CN113908170A (zh) | miR2911在制备抗EV71的药物中的应用 | |
CN115089612B (zh) | 脐带间充质干细胞在预防病毒感染所致肺部疾病中的应用 | |
CN107320726A (zh) | LncRNA‑TUG1在制备调控牙周膜干细胞的干性维持能力的药物中的应用 | |
CN117025607A (zh) | 一种用于抑制病毒的miRNA及其应用 | |
CN111575289A (zh) | 干扰非洲猪瘟病毒基因表达的siRNA及其应用 | |
CN110772483A (zh) | 硫化氢修饰的间充质干细胞外囊泡作为miRNA递送载体在缺氧缺血性脑损伤中的应用 | |
CN114469996B (zh) | 一种包含miR-135b-5p的外泌体及在抗轮状病毒感染中的应用 | |
CN116041477A (zh) | Tdgf1基因在制备治疗衰老相关疾病或逆转细胞衰老的药物中的应用 | |
CN117925607A (zh) | 一种抑制病毒的miRNA及其应用 | |
CN114632155A (zh) | PKA抑制剂H89及其siRNA在制备治疗新型冠状病毒病药物中的应用 | |
CN116121202A (zh) | 一种柯萨奇病毒b组1型毒株及应用 | |
CN108272815B (zh) | EB病毒miR-BART10-5p抑制剂的应用 | |
CN110904056A (zh) | 一种传染性支气管炎病毒rH120-YZS1Δ5a及其构建方法和应用 | |
CN114246847A (zh) | 查尔酮类化合物在治疗冠状病毒感染中的应用 | |
CN117343932B (zh) | 靶向抑制MS4A7基因表达的siRNA及其应用 | |
CN114246853B (zh) | 异阿魏酸在制备用于防治冠状病毒感染的产品中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |